Giandomenico Roviello

Research fellow of the University of Brescia, Section of pharmacology and University Center DIFF-Drug Innovation Forward Future, department of Molecular and Translational Medicine, Unit of molecular therapy and pharmacogenomic, ASST Cremona, Cremona, Italy

Giandomenico Roviello is research fellow of the University of Brescia, Section of pharmacology and University Center DIFF-Drug Innovation Forward Future, department of Molecular and Translational Medicine, Unit of molecular therapy and pharmacogenomic, ASST Cremona, Cremona, Italy. Dr. Roviello graduated from the School of Medicine, Second University of Naples in 2008, with the thesis about the use of Bortezomib in patients with Multiple Myeloma. Dr. Roviello graduated as medical oncologist from University of Siena in 2015, with the thesis about the use of Rechallenge of Docetaxel combined with Epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to Docetaxel and Abiraterone Acetate. His current research interests are genitourinary oncology, and particularly prostate cancer, gastric cancers, breast cancer and targeted anticancer therapies. Dr. Roviello has published 60 articles in peer-reviewed journals. He sits on the editorial board and is a reviewer for several oncological journals. Dr. Roviello’s society memberships include: the European Societies for Medical Oncology, the Italian  Association of Urological Oncology and the Italian Association for gastric research (GIRCG), American society of clinical oncology (ASCO), Italian Association of Medical Oncology (AIOM).